MX2023003426A - Epítopos de celulas t reguladoras retro-inversas. - Google Patents

Epítopos de celulas t reguladoras retro-inversas.

Info

Publication number
MX2023003426A
MX2023003426A MX2023003426A MX2023003426A MX2023003426A MX 2023003426 A MX2023003426 A MX 2023003426A MX 2023003426 A MX2023003426 A MX 2023003426A MX 2023003426 A MX2023003426 A MX 2023003426A MX 2023003426 A MX2023003426 A MX 2023003426A
Authority
MX
Mexico
Prior art keywords
inverso
retro
regulatory
cell epitopes
tregitope
Prior art date
Application number
MX2023003426A
Other languages
English (en)
Spanish (es)
Inventor
Groot Anne De
William Martin
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of MX2023003426A publication Critical patent/MX2023003426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2023003426A 2020-09-25 2021-09-24 Epítopos de celulas t reguladoras retro-inversas. MX2023003426A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063083392P 2020-09-25 2020-09-25
PCT/US2021/052017 WO2022067076A1 (en) 2020-09-25 2021-09-24 Retro-inverso regulatory t cell epitopes

Publications (1)

Publication Number Publication Date
MX2023003426A true MX2023003426A (es) 2023-04-27

Family

ID=80845816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003426A MX2023003426A (es) 2020-09-25 2021-09-24 Epítopos de celulas t reguladoras retro-inversas.

Country Status (8)

Country Link
US (1) US20240173377A1 (cg-RX-API-DMAC7.html)
EP (1) EP4216984A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543801A (cg-RX-API-DMAC7.html)
KR (1) KR20230074517A (cg-RX-API-DMAC7.html)
AU (1) AU2021350011A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193819A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003426A (cg-RX-API-DMAC7.html)
WO (1) WO2022067076A1 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
EP2423220B1 (en) * 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
WO2012142022A1 (en) * 2011-04-11 2012-10-18 The General Hospital Corporation Assays, compositions, systems, kits, and devices for diagnosing typhoid fever
SG11201810470XA (en) * 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
JP7274472B2 (ja) * 2017-10-05 2023-05-16 エピバックス、インコーポレイテッド 制御性t細胞エピトープ

Also Published As

Publication number Publication date
CA3193819A1 (en) 2022-03-31
AU2021350011A1 (en) 2023-05-11
EP4216984A4 (en) 2025-03-05
KR20230074517A (ko) 2023-05-30
AU2021350011A9 (en) 2025-03-13
EP4216984A1 (en) 2023-08-02
WO2022067076A1 (en) 2022-03-31
JP2023543801A (ja) 2023-10-18
US20240173377A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2021001706A (es) Compuestos de anillo fusionado.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX2020005478A (es) Compuestos de sulfonamida y usos de los mismos.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
CR20150491A (es) 3-pirimidin-4-il oxazolidin -2- onas como inhibidores de idh mutante
MY187449A (en) New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
MX2015017103A (es) Celulas beta derivadas de células madre ( sc-beta ) y composiciones y métodos para generarlas.
UY34418A (es) Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
EP4368641A3 (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
MX2015011436A (es) Triazolopiridinas sustituidas y metodos para usarlas.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
ZA202309516B (en) Anti-ccr8 antibodies
PH12016500972A1 (en) Moisture-resistant phosphor compositions and associate methods
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
CR20200202A (es) Metodos de uso y composiciones que contienen dulaglutida
MX2021002286A (es) Terapias de combinacion.
MX2020002045A (es) Composicion herbicida.
SA521431223B1 (ar) Angpt2 أجسام مضادة لـ